###begin article-title 0
The Internally Truncated LRP5 Receptor Presents a Therapeutic Target in Breast Cancer
###end article-title 0
###begin p 1
Conceived and designed the experiments: PB GW. Performed the experiments: PB JS AKO. Analyzed the data: PB JS GA GW. Contributed reagents/materials/analysis tools: AKO. Wrote the paper: GW.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Breast cancer is a common malignant disease, which may be caused by a number of genes deregulated by genomic or epigenomic events. Deregulated WNT/beta-catenin signaling with accumulation of beta-catenin is common in breast tumors, but mutations in WNT signaling pathway components have been rare. An aberrantly spliced internally truncated LRP5 receptor (LRP5Delta666-809, LRP5Delta) was shown recently to be resistant to DKK1 inhibition, and was required for beta-catenin accumulation in hyperparathyroid tumors and parathyroid tumor growth.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 183 190 179 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 374 382 360 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
Here we show, by reverse transcription PCR and Western blot analysis, that LRP5Delta is frequently expressed in breast tumors of different cancer stage (58-100%), including carcinoma in situ and metastatic carcinoma. LRP5Delta was required in MCF7 breast cancer cells for the non-phosphorylated active beta-catenin level, transcription activity of beta-catenin, cell growth in vitro, and breast tumor growth in a xenograft SCID mouse model. WNT3 ligand, but not WNT1 and WNT3A augmented the endogenous beta-catenin activity of MCF7 cells in a DKK1-insensitive manner. Furthermore, an anti-LRP5 antibody attenuated beta-catenin activity, inhibited cell growth, and induced apoptosis in LRP5Delta-positive MCF7 and T-47D breast cancer cells, but not in control cells.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
Our results suggest that the LRP5Delta receptor is strongly implicated in mammary gland tumorigenesis and that its aberrant expression present an early event during disease progression. LRP5 antibody therapy may have a significant role in the treatment of breast cancer.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 437 440 428 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Giles1">[1]</xref>
###xml 441 444 432 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Fuerer1">[7]</xref>
###xml 594 597 585 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Roelink1">[8]</xref>
###xml 599 602 590 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Brennan1">[9]</xref>
###xml 738 742 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Lindvall1">[10]</xref>
###xml 873 877 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-AlHajj1">[11]</xref>
###xml 878 882 869 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Lindvall2">[13]</xref>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
###xml 560 564 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 732 737 <span type="species:ncbi:10090">mouse</span>
Deregulated Wnt signaling with accumulation of beta-catenin in the cytoplasm/nucleus plays an important role in a variety of human cancers. The binding of WNT ligand to frizzled and LRP5/6 cell surface receptors normally leads to inhibition of a "destruction complex" consisting of APC/Axin/GSK-3beta/Ck1/Dvl and other factors, with subsequent accumulation of dephosphorylated stabilized beta-catenin, and regulation of its target genes [1]-[7]. Wnt signaling is involved in mammary gland development and mouse WNT1, WNT3, and WNT10b are clearly implicated in MMTV-induced breast tumorigenesis [8], [9]. The LRP5 receptor was recently shown to be required for mammary ductal stem cell activity and WNT1-induced tumorigenesis in the mouse [10]. This may be of particular importance since subtypes of breast tumors have been suggested to originate from stem cell populations [11]-[13].
###end p 9
###begin p 10
###xml 127 131 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Lin1">[14]</xref>
###xml 132 136 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Prasad1">[19]</xref>
###xml 261 264 255 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Brennan1">[9]</xref>
###xml 266 270 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Candidus1">[20]</xref>
###xml 443 447 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Lindvall2">[13]</xref>
###xml 449 453 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Ai1">[21]</xref>
###xml 454 458 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Suzuki1">[25]</xref>
###xml 106 111 <span type="species:ncbi:9606">human</span>
Aberrant activation of Wnt signaling by cytoplasmic/nuclear beta-catenin has been reported in over 60% of human breast cancers [14]-[19]. Mutation of APC, AXIN or CTNNB1 (beta-catenin), frequently observed in colorectal cancer, is however rare in breast cancer [9], [20]. Other mechanisms proposed to be involved include increased expression of WNT ligands or DVL1, and epigenetic inactivation of WNT pathway antagonists SFRPs, DKK1, and WIF1 [13], [21]-[25].
###end p 10
###begin p 11
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 571 579 553 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 610 617 592 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 683 689 661 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 741 745 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 747 751 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund2">[27]</xref>
###xml 875 879 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bafico1">[28]</xref>
###xml 880 884 854 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Zhang1">[31]</xref>
###xml 974 978 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 626 630 <span type="species:ncbi:10090">mice</span>
A novel mechanism for aberrant activation of Wnt signaling was recently disclosed by us in parathyroid tumors [26]. An aberrantly spliced internally truncated LRP5 receptor (LRP5Delta666-809, LRP5Delta) was found to be expressed in the majority of analyzed parathyroid tumors of both primary and secondary origin, which all displayed cytoplasmic/nuclear beta-catenin. The LRP5Delta receptor responded strongly to WNT3 ligand and was shown to be required for accumulation of nonphosphorylated transcriptionally active beta-catenin, MYC expression, parathyroid cell growth in vitro, and parathyroid tumor growth in vivo in SCID mice. Furthermore, LRP5Delta and stabilizing mutation of CTNNB1 was found to be mutually exclusive in those tumors [26], [27]. The 142 amino acid (666-809) extracellular truncation of LRP5Delta overlaps a binding domain for the LRP5 antagonist DKK1 [28]-[31], and consequently LRP5Delta was found to be insensitive to inhibition by the DKK1 ligand [26].
###end p 11
###begin p 12
We have now extended our analysis of aberrant Wnt signaling to breast carcinoma, and demonstrate a fundamental role for the internally truncated LRP5 receptor in deregulated beta-catenin signaling and tumor growth.
###end p 12
###begin title 13
Results and Discussion
###end title 13
###begin title 14
The LRP5Delta receptor is expressed in breast carcinoma
###end title 14
###begin p 15
###xml 265 266 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 286 290 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Segersten1">[32]</xref>
###xml 357 361 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 470 479 454 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g001">Figure 1A</xref>
###xml 656 665 636 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g001">Figure 1A</xref>
###xml 667 671 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 779 788 755 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g001">Figure 1B</xref>
To investigate whether the internally truncated LRP5Delta666-809 receptor (LRP5Delta) was expressed in breast carcinoma we initially analyzed nineteen breast cancer specimens (T1-T19) that had been randomly selected in a previous study regarding 25-hydroxyvitamin D3 1alpha-hydroxylase [32]. RT-PCR analysis, using primers located in exons 9 and 13 of LRP5 [26], revealed expression of LRP5Delta in 15 out of 17 ductal breast carcinoma and 1 out of 2 lobular carcinoma (Figure 1A). Thus, 84% of the analyzed tumors expressed LRP5Delta. Normal LRP5 (LRP5wt) transcripts were seen in all tumors, and in normal breast tissue specimens (N1-N4) as anticipated (Figure 1A) [26]. Immunoprecipitation and Western blot analysis confirmed expression of LRP5wt and LRP5Delta in the tumors (Figure 1B).
###end p 15
###begin title 16
The LRP5Delta receptor is expressed in breast tumors.
###end title 16
###begin p 17
###xml 192 196 189 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 337 344 334 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004243-t001">Table 1</xref>
Accumulation of active beta-catenin. (A) PCR analysis of cDNA from normal breast tissue (N1-N4) and primary breast cancer (T1-T19). Primers were located in exons 9 and 13 of LRP5 as described [26]. The PCR reaction is not quantitative as the primers compete for the two fragments. A total of sixty-two LRP5 truncated fragments (see also Table 1) were directly sequenced and all contained the same in-frame deletion of 142 amino acids (Delta666-809). (B) Immunoprecipitation and Western blot analysis of LRP5. Tissue numbering corresponds to panel A. Transiently expressed LRP5wt and LRP5Delta shown as markers. (C) Western blot analysis of non-phosphorylated active beta-catenin. Tissue numbering as in panel A.
###end p 17
###begin p 18
###xml 431 440 417 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g001">Figure 1C</xref>
In order to relate accumulation of beta-catenin to expression of LRP5Delta, Western blotting analysis was done on cryosections of the tumor material, including two normal breast tissue specimens. The sixteen tumors with LRP5Delta showed increased accumulation of non-phosphorylated active beta-catenin when compared to the normal breast tissues, and the tumors expressing LRP5wt only (T3, T9, T11) showed similar relative amounts (Figure 1C). Thus, correlation of LRP5Delta expression and aberrant accumulation of non-phosphorylated active beta-catenin was observed in these breast tumors. Stabilizing mutation in beta-catenin exon 3 was not found in the nineteen breast carcinomas (not shown).
###end p 18
###begin p 19
###xml 214 221 210 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004243-t001">Table 1</xref>
###xml 362 369 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
Encouraged by the above results we then screened a commercially available cDNA panel of 96 breast tissue specimens that covered eight cancer stages. LRP5wt and LRP5Delta was observed in 79 out of 95 (83%) samples (Table 1). The remaining samples expressed only LRP5wt and one sample was negative. LRP5Delta was detected in all disease stages including carcinoma in situ and metastases. Thus, expression of LRP5Delta was very common in carcinoma of the breast and may be an early event during cancer progression.
###end p 19
###begin title 20
Expression of LRP5Delta in breast tumor specimens of different cancer stages.
###end title 20
###begin title 21
LRP5Delta causes active beta-catenin signaling in MCF7 cells
###end title 21
###begin p 22
###xml 189 198 181 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2A</xref>
###xml 262 266 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Suzuki1">[25]</xref>
###xml 268 272 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Benhaj1">[33]</xref>
###xml 523 527 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Lin1">[14]</xref>
###xml 529 533 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-vandeWetering1">[34]</xref>
###xml 535 539 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Shekhar2">[35]</xref>
In order to study the consequences of LRP5Delta receptor expression we employed the widely used MCF7 mammary adenocarcinoma cell line which expressed the LRP5Delta receptor but not LRP5wt (Figure 2A), and has been shown to accumulate beta-catenin in the nucleus [25], [33]. We first chose to test the TOPFLASH/FOPFLASH and the pTOPGlow/pFOPGlow TCF luciferase reporters, although conflicting results regarding detection of active beta-catenin signaling using these reporters in breast cancer cell lines have been published [14], [34], [35].
###end p 22
###begin title 23
Endogenous expression of LRP5Delta in MCF7 breast cancer cells is required for accumulation of non-phosphorylated active beta-catenin and transcriptional activation by beta-catenin.
###end title 23
###begin p 24
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 372 376 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 1074 1078 1057 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 722 725 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) PCR of MCF7 cDNA as in panel A. sHPT-1 parathyroid cDNA [26] was used as marker. Direct sequencing confirmed the in-frame deletion of 142 amino acids (Delta666-809). (B) Specificity and efficiency of siRNAs transiently transfected to MCF7 cells. siLRP5wt is directed to wild type transcripts, siLRP5Delta to the truncated transcript, and siLRP5tot to both transcripts [26]. Quantitative real-time PCR of both LRP5 transcripts (LRP5tot, left panel) and immunoprecipitation and Western blot analysis of LRP5 (right panel). (C) Western blot analysis of non-phosphorylated active beta-catenin after siRNA transfection. (D) Transient cotransfections of TOPFLASH/FOPFLASH or pTOPGlow/pFOPGlow TCF/beta-catenin reporter, the CMV-LacZ reference plasmid (left panel), and the indicated siRNAs (right panels) to MCF7 cells. FOPFLASH and pFOPGlow contain mutated binding sites for TCFs, while TOPFLASH and pTOPGlow do not. Luciferase activities were normalized to beta-galactosidase activities. The siRNAs displayed no effect on pFOPGlow (not shown) and FOPFLASH reporter activity [26].
###end p 24
###begin p 25
###xml 228 237 228 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2B</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 606 615 595 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2C</xref>
###xml 801 822 780 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2D, left panel</xref>
###xml 1014 1037 983 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2D, right panels</xref>
###xml 1091 1095 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 1208 1212 1177 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-vandeWetering1">[34]</xref>
Control siRNAs and three highly specific siRNAs directed against LRP5 mRNA were transfected to MCF7 cells. The specificity and silencing potential of the LRP5 siRNAs were ascertained at the mRNA and protein level in MCF7 cells (Figure 2B), as we have shown previously in sHPT-1 parathyroid tumor cells [26]. Transfection of siLRP5Delta, specific for the internally truncated LRP5 receptor, as well as of siLRP5tot directed against exon 13 present in both LRP5 wt and LRP5Delta transcripts, resulted in markedly reduced non-phosphorylated active beta-catenin level, compared to control siRNAs and siLRP5wt (Figure 2C). siLRP5wt was directed to exon 10, not included in the LRP5Delta transcript. sibeta-catenin was included as positive control. Similarily, the endogenous beta-catenin activity in MCF7 (Figure 2D, left panel), as measured by using the TOPFLASH/FOPFLASH or the pTOP/Glow/pFOPGlow TCF/beta-catenin luciferase reporters (6-8 fold), was dependent on maintained expression of LRP5Delta and beta-catenin (Figure 2D, right panels). The various siRNAs displayed no effect on FOPFLASH [26] or pFOPGlow reporter activities (data not shown), which contain mutated TCF binding elements in their promoters [34]. The experiments were done using our in house strain of MCF7 or fresh MCF7 cells from ATCC, which similarily expressed LRP5Delta and showed beta-catenin activity by the TOPFLASH and pTOPGlow assays.
###end p 25
###begin p 26
###xml 67 71 64 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Chamorro1">[36]</xref>
###xml 72 76 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Niida1">[38]</xref>
###xml 323 332 313 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g003">Figure 3A</xref>
###xml 419 428 409 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2D</xref>
###xml 730 739 716 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g003">Figure 3B</xref>
Next we employed the natural beta-catenin responsive DKK1 promoter [36]-[38] instead of the synthetic minimal promoters of TOPFLASH and pTOPGlow. Clearly, the DKK1 promoter activity in transfected MCF7 cells was dependent on the TCF binding elements (TBEs), and also on maintained expression of LRP5Delta and beta-catenin (Figure 3A). Thus, this confirmed the results obtained with the TOPFLASH and pTOPGlow reporters (Figure 2D). Furthermore, we transfected the various siRNAs to MCF7 cells and determined the endogenous DKK1 mRNA expression level. In accordance with the above results, transfection of siLRP5Delta and siLRP5tot, but not of siLRP5wt or Control siRNA resulted in significantly reduced endogenous DKK1 expression (Figure 3B).
###end p 26
###begin title 27
Endogenous expression of LRP5Delta in MCF7 breast cancer cells is required for transcriptional activation of DKK1 by beta-catenin.
###end title 27
###begin p 28
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Niida1">[38]</xref>
###xml 106 109 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 153 156 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 405 408 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) Transient cotransfections of DKK1 promoter luciferase constructs WT short or TBE3,4mut short [38] and CMV-LacZ to MCF7 cells (left panel). WT short, CMV-LacZ, and the indicated siRNAs were transfected (right panel). (B) Endogenous DKK1 mRNA expression in siRNA transfected MCF7 cells as indicated. (C) Transient cotransfections of TOPFLASH/FOPFLASH (left panel) or pTOPGlow/pFOPGlow (right panel) and CMV-LacZ to the indicated number of plated MCF7 cells.
###end p 28
###begin p 29
###xml 152 156 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Lin1">[14]</xref>
###xml 158 162 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-vandeWetering1">[34]</xref>
###xml 164 168 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Shekhar2">[35]</xref>
###xml 286 287 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 308 309 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 379 383 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-vandeWetering1">[34]</xref>
###xml 624 633 618 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g003">Figure 3C</xref>
In an attempt to address possible explanations for conflicting results regarding detection of beta-catenin activity by the TOPFLASH and pTOPGlow assays [14], [34], [35], we performed transfections in the presence of varying cell densities. We routinely plate cells rather sparsely (2x105 cells/35 mm dish, 104 cells/96-well microplates) as compared to for example 80% confluency [34]. As expected, the transfection efficiency (beta-galactosidase activity) was reduced with increasing cell density (not shown), and clearly the TOPFLASH/FOPFLASH as well as the pTOPGlow/pFOPGlow ratios decreased with increasing cell density (Figure 3C). Thus, cell density seemed to be an important determinant of WNT/beta-catenin signaling constituting one possible explanation for published inconsistencies.
###end p 29
###begin p 30
In summary, the results showed that maintained expression of the internally truncated LRP5 receptor in MCF7 cells appeared necessary for accumulation of transcriptionally active beta-catenin.
###end p 30
###begin title 31
WNT3 ligand and LRP5Delta activate transcription synergistically in a DKK1-insensitive manner
###end title 31
###begin p 32
###xml 254 258 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Suzuki1">[25]</xref>
###xml 423 432 416 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g004">Figure 4A</xref>
###xml 1142 1146 1117 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
We reported previously that WNT3 ligand conditioned medium (CM), but not WNT1 and WNT3A, further activated endogenous beta-catenin driven TOPFLASH reporter transcription in sHPT-1 parathyroid tumor cells. WNT1, WNT3 and WNT3A are expressed in MCF7 cells [25], and their effects were determined by transient cotransfections of the TOPFLASH reporter, expression plasmids for LRP5wt or LRP5Delta, and incubation with WNT CMs (Figure 4A). Only WNT3 CM activated the endogenous beta-catenin activity in MCF7 (10-fold). Transfection with LRP5Delta increased the endogenous beta-catenin activity by 8-fold, and this was further strongly enhanced by WNT3 (12-fold), to a total of 96-fold activation compared to control transfected and unstimulated cells (1.0). Transfection of LRP5wt and stimulation with WNT3 CM resulted in 8-fold activation. WNT1 and WNT3A CM activated transcription in the presence of cotransfected LRP5wt (2.5 and 9-fold) and LRP5Delta (3.5 and 2.5-fold). Thus, WNT1 activated transcription in the presence of cotransfected LRP5Delta in these breast tumor cells, while only WNT3 activity was observed in parathyroid tumors cells [26]. This may reflect the collection of expressed frizzled receptors or other cofactors in the two cell lines.
###end p 32
###begin title 33
WNT3 ligand and LRP5Delta activate transcription in a DKK1 insensitive manner.
###end title 33
###begin p 34
###xml 301 305 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 319 328 315 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2D</xref>
###xml 91 94 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 440 443 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
(A) MCF7 cells cotransfected with TOPFLASH, LRP5wt or LRP5Delta666-809 expression vectors, CMV-LacZ reference plasmid, followed by incubation in WNT1, WNT3 or WNT3A conditioned medium (CM). CM was from HEK293T cells transiently transfected with expression vectors for the various WNT and DKK1 ligands [26]. The 8-fold (Figure 2D) endogenous beta-catenin activity is set to 1 (unstimulated, empty vector). (B) Cotransfection of TOPFLASH and CMV-LacZ reference plasmid to MCF7 cells (left panel) or HEK293T control cells (right panel). Incubation in WNT3 and DKK1 CM. HEK293T cells do not express the LRP5Delta receptor.
###end p 34
###begin p 35
###xml 269 273 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 500 509 485 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g004">Figure 4B</xref>
###xml 575 583 557 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The LRP5 antagonist DKK1 requires several amino acid residues included in the LRP5Delta truncation, and indeed the DKK1 ligand could not inhibit endogenous LRP5Delta-induced transcriptional activity in parathyroid tumor cells or in LRP5Delta-transfected HEK 293T cells [26]. Similarily, the presence of DKK1 CM did not inhibit WNT3-induced transcriptional activation in MCF7 cells, while inhibition of WNT3-induced endogenous beta-catenin activity was observed as expected in HEK 293T control cells (Figure 4B). Thus, the DKK1 ligand failed to inhibit beta-catenin signaling in vitro, and this may contribute to the total aberrant signaling level in LRP5Delta-positive breast tumors. DKK1 was found to be expressed in all (n = 16) analyzed breast tumors, as determined by immunohistochemistry (not shown).
###end p 35
###begin p 36
The data presented so far provide compelling evidence for a major role of the internally truncated LRP5 receptor in sustained aberrant beta-catenin signaling in breast cancer.
###end p 36
###begin title 37
###xml 51 59 47 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 64 71 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
LRP5Delta is required for breast tumor cell growth in vitro and in vivo in SCID mice
###end title 37
###begin p 38
###xml 260 269 252 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5A</xref>
###xml 448 452 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
Control siRNA, siLRP5wt, siLRP5Delta, and siLRP5tot were transfected to MCF7 cells and the cell viability was determined 24 hrs and 48 hrs later. Growth inhibition and induction of cell death were seen only with siLRP5Delta, and siLRP5tot at both time points (Figure 5A). Reduced expression of LRP5Delta also lead to growth inhibition and cell death in sHPT-1 parathyroid tumor cells, but not in HeLa cells that do express LRP5wt and not LRP5Delta [26].
###end p 38
###begin title 39
Breast tumor cell growth is dependent on expression of LRP5Delta and continued beta-catenin signaling by the receptor.
###end title 39
###begin p 40
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 853 862 836 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g001">Figure 1B</xref>
###xml 864 873 847 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5C</xref>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:9925">goat</span>
###xml 919 923 <span type="species:ncbi:9925">goat</span>
(A) Cell viability after transient siRNA transfection (24 h/48 h). Inhibition of cell growth was not seen in HeLa cells, that were used as control of toxic effects [26]. (B) Breast tumors from SCID mice injected with MCF7 cells pretransfected for 24 h with the indicated siRNAs. The animals were monitored every day and sacrificed after 5 weeks. The tumors were excised and weighed. (C) Endogenous beta-catenin activity (left panel) and expression of LRP5wt and LRP5Delta as detected by immunoprecipitation and Western blot analysis (right panel) in T-47D breast cancer cells. (D) Effects on MCF7, T-47D and HeLa cell viability (96 h), non-phosphorylated active beta-catenin level (MCF7), and transcription activation (24 h) by beta-catenin (TOPFLASH) in the presence of the anti-LRP5 goat polyclonal antibody that recognizes both LRP5wt and LRP5Delta (Figure 1B, Figure 5C). Incubation without antibody or with normal goat serum showed similar effects (Control). (E) Detection of apoptosis during anti-LRP5 antibody incubation (96 h). Camptothecin treatment was used as positive control.
###end p 40
###begin p 41
###xml 247 256 243 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5B</xref>
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
Tumor growth was then evaluated in a xenograft SCID mouse model. Tumor growth was significantly reduced in transplants of MCF7 cells pretransfected with siLRP5Delta and siLRP5tot, but not with control siRNA when compared to non-transfected cells (Figure 5B). Thus, LRP5Delta appeared to be necessary for breast tumor cell growth both in cell culture and in SCID mice.
###end p 41
###begin p 42
###xml 288 297 277 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g001">Figure 1B</xref>
###xml 299 308 288 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g002">Figure 2B</xref>
###xml 314 323 303 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5C</xref>
###xml 480 489 463 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5D</xref>
###xml 554 563 537 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5D</xref>
###xml 743 747 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Suzuki1">[25]</xref>
###xml 833 842 806 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5C</xref>
###xml 844 848 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Lin1">[14]</xref>
###xml 962 971 932 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5D</xref>
###xml 1099 1108 1069 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004243-g005">Figure 5E</xref>
###xml 211 215 <span type="species:ncbi:9925">goat</span>
If breast tumor cell growth is dependent on LRP5Delta, as strongly suggested by the above experiments, an appropriate anti-LRP5 antibody may reduce cell viability as well as beta-catenin activity. The anti-LRP5 goat polyclonal antibody, that immunoprecipitated both LRP5wt and LRP5Delta (Figure 1B, Figure 2B, and Figure 5C), significantly attenuated the non-phosphorylated active beta-catenin level and the beta-catenin activity in MCF7 cells, and caused reduced cell viability (Figure 5D). This was not observed in HeLa cells that only express LRP5wt (Figure 5D). We also determined effects of the LRP5 antibody on T-47D breast cancer cells, since these cells expressed both LRP5wt and LRP5Delta, showed nuclear accumulation of beta-catenin [25], and displayed endogenous beta-catenin activity as determined by the TOPFLASH assay (Figure 5C) [14]. The LRP5 antibody significantly inhibited cell growth and attenuated beta-catenin activity also in these cells (Figure 5D). Treatment with the anti-LRP5 antibody induced significant apoptosis in both breast cancer cell lines, and not in HeLa cells (Figure 5E).
###end p 42
###begin p 43
###xml 273 277 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Suzuki1">[25]</xref>
###xml 669 673 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Shekhar2">[35]</xref>
Thus, breast tumor cell growth was dependent on maintained expression of LRP5Delta and continued beta-catenin signaling by the receptor. The latter result is in line with the observation that WNT antagonist SFRPs were shown to suppress MCF7 and T-47D cell colony formation [25]. Compared to LRP5wt, LRP5Delta activated beta-catenin driven transcription more strongly in the presence of WNT3 ligand and in a DKK1-insensitive way, both likely contributing to the oncogenic potential of LRP5Delta. In addition to dephosphorylation/phosphorylation, specific ubiquitination by Rad6B has been suggested to control beta-catenin stabilization in MDA-MB-231 breast cancer cells [35]. LRP5Delta was found not to be expressed in this cell line (not shown).
###end p 43
###begin p 44
###xml 455 459 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Barker1">[39]</xref>
###xml 460 464 449 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-ZafirLavie1">[41]</xref>
Although the mechanism by which the LRP5Delta receptor is made and how beta-catenin signaling is activated remain to be understood, the results presented here strongly support an important role of the truncated LRP5 receptor in mammary gland tumorigenesis, and its expression may present an early event during disease progression. Our results furthermore suggest that antibody therapy directed against LRP5Delta, possibly in combination with chemotherapy [39]-[41], present future treatment options of breast cancer.
###end p 44
###begin title 45
Materials and Methods
###end title 45
###begin title 46
Tissue specimens
###end title 46
###begin p 47
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Segersten1">[32]</xref>
###xml 203 211 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
Cryosections of nineteen breast cancer specimens, including seventeen invasive ductal carcinoma and two invasive lobular carcinoma [32] were analyzed. Four apparently normal breast tissue specimens from patients with breast cancer were also included in the analyses. Written informed consent was obtained from the patients and approval was obtained from the local ethical committee, Uppsala. cDNA panels containing 96 breast samples covering eight (0, I, IIA, IIB, IIIA, IIIB, IIIC, IV) cancer stages (American Joint Committee on Cancer) were screened for LRP5wt and LRP5Delta (TissueScan Breast Cancer Tissue qPCR arrays BCRT101 and BCRT102, OriGene Technologies, INC. Rockville, MD, USA).
###end p 47
###begin title 48
Detection of LRP5Delta and DNA sequencing
###end title 48
###begin p 49
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 497 498 493 494 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 459 501 455 497 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCCACAGGATCTCCCTCGAGACCAATAACAACGAC<underline>C</underline>-3&#8242;</named-content>
###xml 532 574 528 570 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTGGACGACTCGATCATGTTGGTGTCCAGGTCGGTC-3&#8242;</named-content>
###xml 708 712 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 965 966 953 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
DNA-free total RNA was prepared from breast tissue cryosections and from MCF7 or T-47D cells, and analyzed by RT-PCR using primary and nested primers spanning positions 1992-2932 of LRP5 mRNA as described [26]. RT-PCR analysis of the two breast tissue cDNA panels was performed using the same primers as above, and in addition the nested PCR was also done using a novel forward primer specific for the Delta666-809 truncation: forward primer (position 2012), 5'-TCCACAGGATCTCCCTCGAGACCAATAACAACGACC-3'; and reverse (position 2543), 5'-TTGGACGACTCGATCATGTTGGTGTCCAGGTCGGTC-3' (GenBank accession number AF064548; ). The underlined C residue in the forward primer is unique to the Delta666-809 truncation point [26]. The PCR resulted in a 105 base pair fragment. The following conditions were used for the LRP5Delta-specific PCR: The nested PCR amplification was performed with 5 ul primary PCR product, 10 pmol of each primer, 0.2 mM dNTPs, 1x PCR buffer, 1,5 mM MgCl2 and 0.25 U Platinum Taq DNA polymerase (Invitrogen Corporation, Carlsbad, California, USA). Denaturation at 95degreesC for 60 s, followed by 40 cycles of denaturation for 10 s, annealing at 60degreesC for 20 s and extension at 72degreesC for 10 s and a final extension at 72degreesC for 7 min. The LRP5Delta-specific PCR is more sensitive since no competition between LRP5wt and LRP5Delta fragments occurs during the PCR. Additional positive tumors of the cDNA panel was detected by this protocol. A total of sixty-two LRP5 truncated fragments were directly sequenced on ABI 373A using the ABI Prism Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems, Foster City, California, USA), and all contained the same in-frame deletion (Delta666-809).
###end p 49
###begin title 50
Cell growth determination and apoptosis
###end title 50
###begin p 51
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 72 78 <span type="species:ncbi:9913">bovine</span>
###xml 454 458 <span type="species:ncbi:9925">goat</span>
###xml 532 536 <span type="species:ncbi:9925">goat</span>
MCF7 cells (2x105) were distributed onto 35-mm dishes in DMEM/10% fetal bovine serum and harvested at 24 and 48 hours after siRNA transfection. The number of viable and nonviable cells were determined by using the NucleoCounter (ChemoMetec A/S, Allerod, Denmark) or by using 96-well microplates (104 cells) and the cell proliferation reagent WST-1 (Roche Diagnostics GmbH, Mannheim, Germany). Cells were incubated for 96 hours without serum, with normal goat serum (DakoCytomation, Glostrup, Denmark, # X0907) or with the anti-LRP5 goat polyclonal antibody (Santa Cruz Biotechnology INC., Santa Cruz, CA, # sc-21390). Quantification of cytoplasmic histone-associated-DNA-fragments (mono- and oligonucleosomes) was done using the Cell Death Detection ELISA PLUS kit (Roche Diagnostics). Camptothecin at 0.1 microg/ml was used as positive control of apoptosis.
###end p 51
###begin title 52
Transfection experiments, Western blotting and immunoprecipitation
###end title 52
###begin p 53
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-vandeWetering1">[34]</xref>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Niida1">[38]</xref>
###xml 679 683 679 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 1042 1043 1039 1040 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1430 1434 1415 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Bjrklund1">[26]</xref>
###xml 1470 1474 1452 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-vanNoort1">[42]</xref>
###xml 689 692 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1089 1092 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1233 1237 <span type="species:ncbi:9925">goat</span>
###xml 1287 1291 <span type="species:ncbi:9925">goat</span>
###xml 1475 1480 <span type="species:ncbi:10090">mouse</span>
###xml 1557 1561 <span type="species:ncbi:9925">goat</span>
MCF7 breast tumor cells were transfected with siRNA at least in triplicates at 2x105 cells/35 mm dish with jetSI-ENDO according to the manufacturers recommendations (Poly-Plus-Transfection SAS, Illkirch, France). The various siRNAs have been described previously [26]. MCF7 cells were transfected with a transfection efficiency of approximately 90% (data not shown). Conditioned medium was produced in transiently transfected HEK293T cells, and TOPFLASH/FOPFLASH (Upstate, Lake Placid, USA), pTOPGlow/pFOPGlow [34] TCF luciferase reporter genes or DKK1 promoter luciferase constructs WT short and TBE3,4mut short [38] were transfected to MCF7 cells as described for sHPT-1 cells [26]. The CMV-LacZ reference plasmid was cotransfected and luciferase activities were normalized to beta-galactosidase activities. We emphasize that the conditioned medium of WNT1, WNT3, WNT3A, and DKK1 used here might contain uncharacterized signaling molecules induced by the WNTs or DKK1. MCF7, T-47D, and HeLa cells were transfected in 96-well microplates (104 cells) with 0.15 microg TOPFLASH, 0.1 microg CMV-LacZ using 0.5 microl jetPEI (Poly-Plus-Transfection SAS). After 24 h, the cells were incubated further for 24 h without serum, with normal goat serum (DakoCytomation, # X0907) or the anti-LRP5 goat polyclonal antibody (Santa Cruz Biotechnology INC., # sc-21390). Western blotting and immunoprecipitation analyses were done as described [26] using the anti-active-beta-catenin [42] mouse monoclonal antibody (Upstate, Lake Placid, USA, # 05-665) and the anti-LRP5 goat polyclonal antibody (Santa Cruz Biotechnology INC., # sc-21390).
###end p 53
###begin title 54
Quantitative PCR analysis of LRP5tot and DKK1 mRNA
###end title 54
###begin p 55
###xml 231 258 231 258 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ATCGACTGTATCCCC GGGGC-3&#8242;</named-content>
###xml 269 295 269 295 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CACCACGCGCTGGCACACAA-3&#8242;</named-content>
###xml 308 340 308 340 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGGACTGTG ACGCCATCTGCC TGC-3&#8242;</named-content>
###xml 519 547 519 547 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTCTCCCTCTTGAGTCCTTCTG-3&#8242;</named-content>
###xml 562 589 562 589 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGAGTTCACTGCATTTGGAT-3&#8242;</named-content>
cDNA from siRNA transfected MCF7 cells was prepared as described above. The following mRNA-specific PCR primers and labeled probe (5'FAM-sequence-3'TAMRA) were used for quantitative real-time RT-PCR analysis. For LRP5tot: forward, 5'-ATCGACTGTATCCCC GGGGC-3'; reverse, 5'-CACCACGCGCTGGCACACAA-3'; and probe, 5'-CGGACTGTG ACGCCATCTGCC TGC-3'. For 28S rRNA, the Ribosomal RNA Control Reagents (VIC probe) was used (Applied Biosystems, Foster City, California, USA). The following PCR primers were used for DKK1: forward, 5'-TTCTCCCTCTTGAGTCCTTCTG-3'; and reverse, 5'-AGGAGTTCACTGCATTTGGAT-3'. PCR reactions were performed on MyiQ Single-Color Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, California, USA) using the TaqMan PCR core Reagent Kit (Applied Biosystems) or the iQ SYBR Green Supermix (Bio-Rad Laboratories, Inc.). Each cDNA sample was analyzed in triplicate. Standard curves for the expressed genes were established by amplifying a purified PCR fragment covering the sites for probes and primers.
###end p 55
###begin title 56
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse xenograft model
###end title 56
###begin p 57
###xml 430 431 426 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 769 773 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004243-Workman1">[43]</xref>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
Two to three week old female Fox Chase severe combined immunodeficient mice (SCID) were used (Taconic, Denmark). The mice were anesthetized with isoflurane (Forene; Abbott, Abbott Park, IL, USA) during the manipulations. Both flanks of each animal were injected subcutaneously (total 200 microl) with MCF7 cells together (1:1) with BD Matrigel Matrix (BD Biosciences Clontech, Palo Alto, California, USA), after transfection of 106 cells for 24 hours. The animals were monitored every day and sacrificed after 5 weeks. The animal experiments was approved by the Uppsala University board of animal experimentation and was performed according to the United Kingdom Coordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia [43].
###end p 57
###begin title 58
Statistical analysis
###end title 58
###begin p 59
###xml 9 10 9 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Unpaired t test was used for all statistical analyses. Values are presented as arithmetrical mean+/-SEM. A p value of <0.05 was considered significant.
###end p 59
###begin p 60
We are grateful to Drs. H. Clevers and A. Niida for the pTOPGlow/pFOPGlow and DKK1 promoter constructs, respectively. We thank B. Bondeson and P. Lillhager for skilful and extensive technical assistance.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
Caught up in a Wnt storm: Wnt signaling in cancer.
###end article-title 62
###begin article-title 63
The Wnt signaling pathway and its role in tumor development.
###end article-title 63
###begin article-title 64
WNT and beta-catenin signalling: diseases and therapies.
###end article-title 64
###begin article-title 65
Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors.
###end article-title 65
###begin article-title 66
WNT signaling pathway and stem cell signaling network.
###end article-title 66
###begin article-title 67
The many ways of Wnt in cancer.
###end article-title 67
###begin article-title 68
Wnt signalling in development and disease. Max Delbruck center for molecular medicine meeting on Wnt signaling in development and disease.
###end article-title 68
###begin article-title 69
###xml 102 107 <span type="species:ncbi:10090">mouse</span>
Amplification and proviral activation of several Wnt genes during progression and clonal variation of mouse mammary tumors.
###end article-title 69
###begin article-title 70
Wnt proteins in mammary development and cancer.
###end article-title 70
###begin article-title 71
The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1 induced tumorigenesis.
###end article-title 71
###begin article-title 72
Prospective identification of tumorigenic breast cancer cells.
###end article-title 72
###begin article-title 73
Wnt/beta-catenin signaling in cancer stemness and malignant behaviour.
###end article-title 73
###begin article-title 74
Wnt signaling, stem cells, and the cellular origin of breast cancer.
###end article-title 74
###begin article-title 75
Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.
###end article-title 75
###begin article-title 76
Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.
###end article-title 76
###begin article-title 77
beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.
###end article-title 77
###begin article-title 78
Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome.
###end article-title 78
###begin article-title 79
Essential role of T-cell factor/beta-catenin in regulation of Rad6B: a potential mechanism for Rad6B overexpression in breast cancer cells.
###end article-title 79
###begin article-title 80
Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
###end article-title 80
###begin article-title 81
###xml 66 71 <span type="species:ncbi:9606">human</span>
No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas.
###end article-title 81
###begin article-title 82
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer.
###end article-title 82
###begin article-title 83
Wnt signaling pathway in mammary gland development and carcinogenesis.
###end article-title 83
###begin article-title 84
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.
###end article-title 84
###begin article-title 85
Beta-catenin/LEF-1 signalling in breast cancer-central players activated by a plethora of inputs.
###end article-title 85
###begin article-title 86
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer.
###end article-title 86
###begin article-title 87
An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling.
###end article-title 87
###begin article-title 88
###xml 129 137 <span type="species:ncbi:9606">patients</span>
Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients.
###end article-title 88
###begin article-title 89
Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow.
###end article-title 89
###begin article-title 90
LDL-receptor-related protein 6 is a receptor for Dickkopf proteins.
###end article-title 90
###begin article-title 91
Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6.
###end article-title 91
###begin article-title 92
The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd.
###end article-title 92
###begin article-title 93
25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.
###end article-title 93
###begin article-title 94
###xml 49 54 <span type="species:ncbi:9606">human</span>
Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
###end article-title 94
###begin article-title 95
Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling.
###end article-title 95
###begin article-title 96
Rad6B is a positive regulator of beta-catenin stabilization.
###end article-title 96
###begin article-title 97
FGF-20 and DKK1 are transcriptional targets of beta-catenin and FGF-20 is implicated in cancer and development.
###end article-title 97
###begin article-title 98
###xml 102 107 <span type="species:ncbi:9606">human</span>
The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer.
###end article-title 98
###begin article-title 99
DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway.
###end article-title 99
###begin article-title 100
Mining the Wnt pathway for cancer therapeutics.
###end article-title 100
###begin article-title 101
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Current role of antibody therapy in patients with metastatic colorectal cancer.
###end article-title 101
###begin article-title 102
Novel antibodies as anticancer agents.
###end article-title 102
###begin article-title 103
Wnt signaling controls the phosphorylation status of beta-catenin.
###end article-title 103
###begin article-title 104
UKCCCR guidelines for the welfare of animals in experimental neoplasia.
###end article-title 104
###begin p 105
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: A patent is filled (USA) for "LRP5 and LRP6 receptors in cancer treatment", number WO2005048913 (PB, GA, GW). The authors declare that they have no other competing interests.
###end p 105
###begin p 106
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 94 99 <span type="species:ncbi:9689">Lions</span>
Funding: This work was supported by the Swedish Research Council, Swedish Cancer Society, and Lions Fund for Cancer Research. The funders had no role in study design, data collection and analysis, decision to publish or the preparation of the manuscript.
###end p 106

